Recent events
Recent events tied to this brand in public sources.
Back to profile26 entries · Page 2 of 2
2020
Thomas C. Freyman elected to AbbVie board
AbbVie’s board elected Thomas C. Freyman, Abbott’s retired executive vice president and chief financial officer, to join the board in connection with the Allergan deal closing.
2020
AbbVie completes acquisition of Allergan
AbbVie announced that it had completed its acquisition of Allergan; the transaction had received the required government regulatory approvals and approval from the High Court of Ireland.
2019
Alkem Laboratories agrees to acquire Dronabinol-related assets from AbbVie
Alkem Laboratories entered into an asset purchase agreement with AbbVie for certain assets related to the active pharmaceutical ingredient Dronabinol, including Marinol-related intellectual property and regulatory assets. The stated acquisition cost is USD 10 million plus working capital adjustments on closing.
2019
Drugmakers agree to reduce prices of some medicines in China
Chinese regulators said pharmaceutical companies, including Roche and Novartis, agreed to reduce the China prices of some newer medicines by an average of 61% to enter the national medical insurance reimbursement list.
2019
AbbVie updates 2019 earnings guidance
AbbVie updated its full-year 2019 GAAP diluted EPS guidance range to $5.08–$5.10 and raised its adjusted diluted EPS guidance range to $8.90–$8.92.
2019
AbbVie and Cystic Fibrosis Foundation announce licensing collaboration
AbbVie and the Cystic Fibrosis Foundation announced a strategic collaboration under which AbbVie will develop a CFTR potentiator compound licensed from the Foundation and advance it into clinical development for potential use in combination treatments for cystic fibrosis.